



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

|   |           |   |
|---|-----------|---|
| <b>(51) International Patent Classification <sup>6</sup> :</b><br><b>A61K 31/557</b>  | <b>A1</b> | <b>(11) International Publication Number:</b> <b>WO 99/02165</b><br><b>(43) International Publication Date:</b> 21 January 1999 (21.01.99)  |
| <b>(21) International Application Number:</b> PCT/SE98/01368<br><b>(22) International Filing Date:</b> 10 July 1998 (10.07.98)<br><b>(30) Priority Data:</b><br>9702706-4                      11 July 1997 (11.07.97)                      SE<br><b>(71) Applicant (for all designated States except US):</b> PHARMACIA & UPJOHN AB [SE/SE]; S-112 87 Stockholm (SE).<br><b>(72) Inventors; and</b><br><b>(75) Inventors/Applicants (for US only):</b> STJERNSCHANTZ, Johan [FI/SE]; Villavägen 1 B, S-752 38 Uppsala (SE). RESUL, Bahram [SE/SE]; Vitkålgatan 112, S-754 49 Uppsala (SE). LAKE, Staffan [SE/SE]; Farkostvägen 8, S-181 35 Lidingö (SE).<br><b>(74) Agents:</b> SVANSTRÖM, Pär et al.; Pharmacia & Upjohn AB, S-751 82 Uppsala (SE). |           | <b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).<br><br><b>Published</b><br><i>With international search report.</i> |
| <b>(54) Title:</b> PROSTAGLANDIN DERIVATIVES DEVOID OF SIDE-EFFECTS FOR THE TREATMENT OF GLAUCOMA   |           |   |
| <b>(57) Abstract</b><br><p>A new method and compositions for the treatment of glaucoma and ocular hypertension are described. The method is based on the usage of EP<sub>1</sub> prostanoid receptor agonists which effectively reduce the intraocular pressure but have no, or reduced effect on iris pigmentation. The prostaglandin analogue which is an EP<sub>1</sub> selective agonist is applied topically on the eye.</p>   |           |   |
|   |           |   |